{"id":"NCT02065557","sponsor":"AbbVie","briefTitle":"Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis","officialTitle":"A Multicenter, Randomized, Double-Blind Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-10-13","primaryCompletion":"2020-02-07","completion":"2020-02-07","firstPosted":"2014-02-19","resultsPosted":"2020-10-05","lastUpdate":"2020-10-05"},"enrollment":101,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Ulcerative Colitis"],"interventions":[{"type":"BIOLOGICAL","name":"Adalimumab","otherNames":["Humira"]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Adalimumab Induction Standard Dose","type":"EXPERIMENTAL"},{"label":"Adalimumab Induction High Dose","type":"EXPERIMENTAL"},{"label":"Adalimumab Induction High Dose - Open Label","type":"EXPERIMENTAL"},{"label":"Maintenance Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Adalimumab Maintenance Standard Dose","type":"EXPERIMENTAL"},{"label":"Adalimumab Maintenance High Dose","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to demonstrate the efficacy and safety, and to assess the pharmacokinetics of adalimumab administered subcutaneously (SC) in pediatric subjects with moderate to severe ulcerative colitis (UC).","primaryOutcome":{"measure":"Co-Primary Endpoint 1: Percentage of Participants Who Achieved Clinical Remission as Measured by Partial Mayo Score (PMS) at Week 8 - Induction Period","timeFrame":"Week 8","effectByArm":[{"arm":"Main Study: I-SD","deltaMin":43.3,"sd":null},{"arm":"Main Study: I-HD","deltaMin":59.6,"sd":null},{"arm":"Main Study: I-SD + I-HD","deltaMin":53.2,"sd":null},{"arm":"Main Study: I-HD-OL","deltaMin":68.8,"sd":null},{"arm":"Integrated Study (Main + Japan Sub-Study): I-SD","deltaMin":40.6,"sd":null},{"arm":"Integrated Study (Main + Japan Sub-Study): I-HD","deltaMin":58.8,"sd":null},{"arm":"Integrated Study (Main + Japan Sub-Study): I-SD + I-HD","deltaMin":51.8,"sd":null},{"arm":"Integrated Study (Main + Japan Sub-Study): I-HD-OL","deltaMin":66.7,"sd":null}],"pValues":[{"comp":"OG002","p":"< 0.001"},{"comp":"OG001","p":"< 0.001"},{"comp":"OG000","p":"0.382"},{"comp":"OG006","p":"< 0.001"},{"comp":"OG005","p":"< 0.001"},{"comp":"OG004","p":"0.344"}]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":60,"countries":["United States","Australia","Austria","Belgium","Canada","Czechia","Hungary","Israel","Japan","New Zealand","Poland","Slovakia","Spain","United Kingdom"]},"refs":{"pmids":["34153231"],"seeAlso":["http://rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":32},"commonTop":["HEADACHE","NASOPHARYNGITIS","COLITIS ULCERATIVE","UPPER RESPIRATORY TRACT INFECTION","ANAEMIA"]}}